<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="lafora" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">lafora</book-part-id>
      <title-group>
        <title>Progressive Myoclonus Epilepsy, Lafora Type</title>
        <alt-title alt-title-type="alt-title">Synonyms: Lafora Body Disease, Lafora Disease</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jansen</surname>
            <given-names>Anna C</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="lafora.Tc.aff1"/>
          <xref ref-type="aff" rid="lafora.Tc.aff2"/>
          <email>anna.jansen@uzbrussel.be</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Andermann</surname>
            <given-names>Eva</given-names>
          </name>
          <degrees>MD, PhD, FCCMG</degrees>
          <xref ref-type="aff" rid="lafora.Tc.aff3"/>
          <xref ref-type="aff" rid="lafora.Tc.aff4"/>
          <email>eva.andermann@mcgill.ca</email>
        </contrib>
      </contrib-group>
      <aff id="lafora.Tc.aff1">Pediatric Neurology Unit<break/>Department of Pediatrics<break/>Universitair Ziekenhuis Brussel<break/>Brussels, Belgium</aff>
      <aff id="lafora.Tc.aff2">Department of Health Sciences<break/>Vrije Universiteit Brussel<break/>Brussels, Belgium</aff>
      <aff id="lafora.Tc.aff3">Director, Neurogenetics Unit <break/>Montreal Neurological Hospital &#x00026; Institute<break/>Montreal, Quebec, Canada</aff>
      <aff id="lafora.Tc.aff4">Professor, Departments of Neurology &#x00026; Neurosurgery and Human Genetics <break/>McGill University <break/>Montreal, Quebec, Canada</aff>
      <pub-history>
        <date date-type="created">
          <day>28</day>
          <month>12</month>
          <year>2007</year>
        </date>
        <date date-type="updated">
          <day>22</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="trimethylaminuria" document-type="chapter">Primary Trimethylaminuria</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ppr-dysp" document-type="chapter">Progressive Pseudorheumatoid Dysplasia</related-object>
      <abstract id="lafora.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Lafora disease (LD) is characterized by fragmentary, symmetric, or generalized myoclonus and/or generalized tonic-clonic seizures, visual hallucinations (occipital seizures), and progressive neurologic degeneration including cognitive and/or behavioral deterioration, dysarthria, and ataxia beginning in previously healthy adolescents between ages 12 and 17 years. The frequency and intractability of seizures increase over time. Status epilepticus is common. Emotional disturbance and confusion are common at or soon after onset of seizures and are followed by dementia. Dysarthria and ataxia appear early, spasticity late. Most affected individuals die within ten years of onset, usually from status epilepticus or from complications related to nervous system degeneration.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis is usually based on clinical and EEG findings and detection of two pathogenic variants in one of the two genes known to be associated with LD: <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> (<italic toggle="yes">EPM2B</italic>). On rare occasion skin biopsy to detect Lafora bodies is necessary to confirm the diagnosis.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Antiepileptic drugs (AEDs) are effective against generalized seizures.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Overmedication in treating drug-resistant myoclonus is a risk. Gastrostomy feedings can decrease the risk of aspiration pneumonia when disease is advanced.</p>
          <p><italic toggle="yes">Surveillance:</italic> Clinical and psychosocial evaluation at three- to six-month intervals throughout the teenage years.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Phenytoin, and possibly carbamazepine, oxcarbazepine, and lamotrigine.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Lafora disease is inherited in an autosomal recessive manner. Heterozygotes (carriers) are asymptomatic. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for at-risk pregnancies are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="lafora.Diagnosis">
        <title>Diagnosis</title>
        <sec id="lafora.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of Lafora disease (LD) is suspected in a previously healthy older child or adolescent (usually in the early teens) who has the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Fragmentary, symmetric, or generalized myoclonus <bold>and/or</bold> generalized tonic-clonic seizures</p>
            </list-item>
            <list-item>
              <p>Visual hallucinations (occipital seizures)</p>
            </list-item>
            <list-item>
              <p>Progressive neurologic degeneration including cognitive and/or behavioral deterioration, dysarthria, ataxia, and, at later stages, spasticity and dementia</p>
            </list-item>
            <list-item>
              <p>Slowing of background activity, loss of &#x003b1;-rhythm and sleep features, and photosensitivity on early EEGs</p>
            </list-item>
            <list-item>
              <p>Periodic acid Schiff-positive intracellular inclusion bodies (Lafora bodies) on skin biopsy</p>
            </list-item>
            <list-item>
              <p>Normal MRI of the brain at onset</p>
            </list-item>
          </list>
          <p>See <xref ref-type="table" rid="lafora.T.clinical_evaluation_of_lafora_d">Table 1</xref>.</p>
          <table-wrap id="lafora.T.clinical_evaluation_of_lafora_d" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Clinical Evaluation of Lafora Disease</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Evaluation Type</th>
                  <th id="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">At Onset</th>
                  <th id="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Later in Disease Course</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>General physical examination, including liver and spleen sizes</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Neurologic examination, including fundi and reflexes</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Dysarthria, ataxia, spasticity; fundi remain normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Mental state examination</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Visual hallucinations (epileptic), depressed mood, cognitive deficits</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Increased hallucinations, agitation, and dementia with predominantly frontal cognitive impairment affecting mainly performance ability and executive function</td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>EEG</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal or slow background, loss of &#x003b1;-rhythm and sleep features; photosensitivity is common</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Slow background, paroxysms of generalized irregular spike-wave discharges with occipital predominance, and focal, especially occipital, abnormalities</td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Visual, somatosensory, and auditory brain stem evoked potentials</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">High-voltage visual and somatosensory evoked potentials</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Amplitudes may return to normal size; prolongation of brain stem and central latencies</td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Nerve conduction studies</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>MRI of the brain</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal or atrophy&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Proton MR spectroscopy of the brain</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Data not available</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Reduced NAA/creatine ratio in frontal and occipital cortex, basal ganglia, and cerebellum; reduced NAA/myoinositol ratio in frontal gray and white matter; reduced NAA/choline ratio in cerebellum&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Transcranial magnetic stimulation (TMS)</bold>
                  </td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Not applicable</td>
                  <td headers="hd_h_lafora.T.clinical_evaluation_of_lafora_d_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Defective short intracortical inhibition (SICI): inhibition at ISI 6 ms and ISI 10 ms; defective long interval cortical inhibition (LICI)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p><xref ref-type="bibr" rid="lafora.REF.minassian.2001.21">Minassian [2001]</xref>, <xref ref-type="bibr" rid="lafora.REF.minassian.2002.199">Minassian [2002]</xref>, <xref ref-type="bibr" rid="lafora.REF.villanueva.2006.788">Villanueva et al [2006]</xref>, <xref ref-type="bibr" rid="lafora.REF.pichiecchio.2008.342">Pichiecchio et al [2008]</xref>, <xref ref-type="bibr" rid="lafora.REF.altindag.2009.359">Altindag et al [2009]</xref>, <xref ref-type="bibr" rid="lafora.REF.canafoglia.2010.232">Canafoglia et al [2010]</xref></p>
              </fn>
              <fn id="lafora.TF.1.1">
                <label>1. </label>
                <p>No significant correlation observed with disease evolution</p>
              </fn>
              <fn id="lafora.TF.1.2">
                <label>2. </label>
                <p>At least two years after onset of symptoms</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="lafora.Testing">
          <title>Testing</title>
          <p><bold>Skin biopsy</bold> reveals Lafora bodies [<xref ref-type="bibr" rid="lafora.REF.carpenter.1974.531">Carpenter et al 1974</xref>, <xref ref-type="bibr" rid="lafora.REF.carpenter.1981.1564">Carpenter &#x00026; Karpati 1981</xref>] composed of starch-like polyglucosans, which are insufficiently branched and hence insoluble glycogen molecules. Lafora bodies are present in either eccrine duct cells or in apocrine myoepithelial cells.</p>
          <p>Note: (1) Normal PAS-positive apical granules in secretory apocrine cells found in the axilla can be mistaken for Lafora bodies; thus, biopsy of skin outside the axilla and genital regions is favored, as eccrine duct cell Lafora bodies are unmistakable [<xref ref-type="bibr" rid="lafora.REF.andrade.2003.1611">Andrade et al 2003</xref>]. (2) Interpretation of findings on skin biopsy involves a risk of false negative results [<xref ref-type="bibr" rid="lafora.REF.lesca.2010.1691">Lesca et al 2010</xref>], especially in newly symptomatic individuals, and a risk of false positive results because of the difficulty in distinguishing Lafora bodies from normal PAS-positive polysaccharides in apocrine glands [<xref ref-type="bibr" rid="lafora.REF.drury.1993.102">Drury et al 1993</xref>, <xref ref-type="bibr" rid="lafora.REF.andrade.2003.1611">Andrade et al 2003</xref>]. (3) Although sequencing and deletion/duplication analysis of <italic toggle="yes">EPM2A</italic> and <italic toggle="yes">NHLRC1</italic> represent the gold standard for confirming the diagnosis, skin biopsy remains a useful diagnostic tool in individuals with a clinical diagnosis of Lafora disease in whom no pathogenic variant can be identified.</p>
          <sec id="lafora.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Genes.</bold> The two genes in which pathogenic variants are known to cause LD are <italic toggle="yes">EPM2A</italic> [<xref ref-type="bibr" rid="lafora.REF.minassian.1998.171">Minassian et al 1998</xref>] and <italic toggle="yes">NHLRC1</italic> (also known as <italic toggle="yes">EPM2B</italic>) [<xref ref-type="bibr" rid="lafora.REF.chan.2003b.125">Chan et al 2003b</xref>]. See <xref ref-type="table" rid="lafora.T.summary_of_molecular_genetic_te">Table 2</xref>.</p>
            <table-wrap id="lafora.T.summary_of_molecular_genetic_te" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Progressive Myoclonus Epilepsy, Lafora Type</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Lafora Disease Attributed to Pathogenic Variants in This Gene</th>
                    <th id="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">EPM2A</italic>
                    </td>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">22%-70%&#x000a0;<sup>2,&#x000a0;3,&#x000a0;4,&#x000a0;5,&#x000a0;6</sup></td>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>7,&#x000a0;8</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>9,&#x000a0;10</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">NHLRC1 (EPM2B)</italic>
                    </td>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">27%-73%&#x000a0;<sup>2,&#x000a0;3,&#x000a0;4,&#x000a0;5,&#x000a0;6</sup></td>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>7, 8</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>9,&#x000a0;10</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>11</sup></td>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                    <td headers="hd_h_lafora.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="lafora.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="lafora" object-id="lafora.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="lafora.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="lafora.TF.2.2">
                  <label>2. </label>
                  <p><xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al [2005]</xref> found pathogenic variants in 97% (75/77) of families with LD: <italic toggle="yes">EPM2A</italic> (70%) and <italic toggle="yes">NHLRC1</italic> (27%).</p>
                </fn>
                <fn id="lafora.TF.2.3">
                  <label>3. </label>
                  <p><xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al [2006]</xref> found pathogenic variants in 21/22 (95%) of families with LD: <italic toggle="yes">EPM2A</italic> (22%) and <italic toggle="yes">NHLRC1</italic> (73%).</p>
                </fn>
                <fn id="lafora.TF.2.4">
                  <label>4. </label>
                  <p><xref ref-type="bibr" rid="lafora.REF.lohi.2006.399">Lohi et al [2006]</xref> found pathogenic variants in 88% (75/85) of families with LD: <italic toggle="yes">EPM2A</italic> (45%) and <italic toggle="yes">NHLRC1</italic> (43%).</p>
                </fn>
                <fn id="lafora.TF.2.5">
                  <label>5. </label>
                  <p><xref ref-type="bibr" rid="lafora.REF.singh.2006.e48">Singh et al [2006]</xref> found pathogenic variants in 84% (23/28) of families with LD: <italic toggle="yes">EPM2A</italic> (54%) and <italic toggle="yes">NHLRC1</italic> (34%).</p>
                </fn>
                <fn id="lafora.TF.2.6">
                  <label>6. </label>
                  <p>The marked variations may reflect ethnic differences or chance variation and small sample size.</p>
                </fn>
                <fn id="lafora.TF.2.7">
                  <label>7. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="lafora.TF.2.8">
                  <label>8. </label>
                  <p>Studies of the combined pathogenic variant detection frequency of sequence analysis of <italic toggle="yes">EPM2A</italic> and <italic toggle="yes">NHLRC1</italic> revealed that between 88% and 97% of pathogenic variants in these two genes can be detected using sequence analysis alone [<xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.lohi.2006.399">Lohi et al 2006</xref>].</p>
                </fn>
                <fn id="lafora.TF.2.9">
                  <label>9. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="lafora.TF.2.10">
                  <label>10. </label>
                  <p>The proportion of pathogenic variants in <italic toggle="yes">EPM2A</italic> and <italic toggle="yes">NHLRC1</italic> not detected by sequence analysis that are attributable to deletions is unknown. In the one study that screened for suspected deletions in three individuals with a single heterozygous sequence-detectable pathogenic variant, <xref ref-type="bibr" rid="lafora.REF.lohi.2007.996">Lohi et al [2007]</xref> found three deletions in three families, one in <italic toggle="yes">EPM2A</italic> and two in <italic toggle="yes">NHLRC1</italic>. See also <xref ref-type="sec" rid="lafora.Molecular_Genetics">Molecular Genetics</xref>. Kecmanovi&#x00107; et al reported an affected individual with a homozygous deletion encompassing the entire <italic toggle="yes">NHLRC1</italic> gene and with a clinical course more progressive than in most individuals with mutation of <italic toggle="yes">NHLRC1</italic> [<xref ref-type="bibr" rid="lafora.REF.kecmanovi_.2013.170">Kecmanovi&#x00107; et al 2013</xref>].</p>
                </fn>
                <fn id="lafora.TF.2.11">
                  <label>11. </label>
                  <p>Pathogenic variants in at least one other gene also cause LD. <xref ref-type="bibr" rid="lafora.REF.chan.2004.565">Chan et al [2004]</xref> described one family with three individuals with biopsy-confirmed LD and no identifiable pathogenic variant in either <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic>. Linkage and haplotype analyses excluded both loci from causative involvement in this family, providing indirect evidence for a third locus for LD. The findings were supported by independent studies [<xref ref-type="bibr" rid="lafora.REF.singh.2005.347">Singh et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2006.e48">Singh et al 2006</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Interpretation of test results.</bold> Deletions should be suspected:</p>
            <list list-type="bullet">
              <list-item>
                <p>In affected individuals who have a single heterozygous pathogenic variant in one of the genes;</p>
              </list-item>
              <list-item>
                <p>In affected individuals who have an apparently homozygous pathogenic variant in one of the genes, but the pathogenic variant is carried by only one parent.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="lafora.Testing_Strategy">
          <title>Testing Strategy</title>
          <sec id="lafora.To_ConfirmEstablish_the_Diagnosis">
            <title>To Confirm/Establish the Diagnosis in a Proband</title>
            <p><bold>Molecular genetic testing.</bold> Approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive genomic testing</bold>:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Serial single-gene testing.</bold> One strategy for molecular diagnosis of a proband suspected of having LD is targeted analyses of <italic toggle="yes">NHLRC1</italic> or <italic toggle="yes">EPM2A</italic>. Identification of biallelic pathogenic variants in either <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> is required:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Sequence analysis of <italic toggle="yes">NHLRC1</italic> may be considered first.</p>
                  </list-item>
                  <list-item>
                    <p>If no pathogenic variants are identified in <italic toggle="yes">NHLRC1,</italic> sequence analysis of <italic toggle="yes">EPM2A</italic> should be pursued.</p>
                  </list-item>
                  <list-item>
                    <p>If one pathogenic variant is identified in <italic toggle="yes">NHLRC1 or EPM2A,</italic> consider deletion/duplication analysis of that gene (see <xref ref-type="sec" rid="lafora.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>, <bold>Interpretation of test results</bold>).</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Multi-gene panel.</bold> Another strategy for molecular diagnosis of a proband suspected of having LD is use of a multi-gene panel which includes <italic toggle="yes">EPM2A</italic>, <italic toggle="yes">NHLRC1</italic>, and other genes of interest (see <xref ref-type="sec" rid="lafora.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
                <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
              </list-item>
              <list-item>
                <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of LD. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
              </list-item>
            </list>
            <p>Note: Although some evidence suggests that persons with <italic toggle="yes">NHLRC1</italic>-associated LD tend to live longer than those with <italic toggle="yes">EPM2A</italic>-associated LD [<xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al 2006</xref>], the clinical manifestations of LD caused by pathogenic variants in either gene are so similar that it is not possible to predict which gene will be mutated in any given individual.</p>
            <p><bold>Skin biopsy.</bold> Lafora bodies may be detected on skin biopsy. Note: Lafora bodies may also be identified in individuals with early-onset Lafora body disease; see <xref ref-type="sec" rid="lafora.Differential_Diagnosis">Differential Diagnosis</xref>.</p>
          </sec>
        </sec>
      </sec>
      <sec id="lafora.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="lafora.Clinical_Description">
          <title>Clinical Description</title>
          <p>Lafora disease (LD) typically starts between ages 12 and 17 years, after a period of apparently normal development. Many affected individuals experience isolated febrile or nonfebrile convulsions in infancy or early in childhood. Intractable seizures rarely begin as early as age six years. In families with more than one affected child, clinical signs such as subtle myoclonus, visual hallucinations, or headaches are noted earlier in subsequent affected children than in the proband [<xref ref-type="bibr" rid="lafora.REF.minassian.2000b.341">Minassian et al 2000b</xref>, <xref ref-type="bibr" rid="lafora.REF.minassian.2002.199">Minassian 2002</xref>]. Intra- and interfamilial variability in age at onset is considerable [<xref ref-type="bibr" rid="lafora.REF.g_mezabad.2007.1011">G&#x000f3;mez-Abad et al 2007</xref>, <xref ref-type="bibr" rid="lafora.REF.lohi.2007.996">Lohi et al 2007</xref>].</p>
          <p>The main seizure types in LD include myoclonic seizures and occipital seizures, although generalized tonic-clonic seizures, atypical absence seizures, and atonic and complex partial seizures may occur.</p>
          <p>Myoclonus can be fragmentary, symmetric, or massive (generalized). It occurs at rest and is exaggerated by action, photic stimulation, or excitement. Both negative (loss of tone) and positive (jerking) myoclonus can occur. Myoclonus usually disappears with sleep. Trains of massive myoclonus with relative preservation of consciousness have been reported. Myoclonus is the primary reason for early wheelchair dependency. In the advanced stages of the disease, affected individuals often have continuous generalized myoclonus.</p>
          <p>Occipital seizures present as transient blindness, simple or complex visual hallucinations, photomyoclonic or photoconvulsive seizures, or migraine with scintillating scotomata [<xref ref-type="bibr" rid="lafora.REF.berkovic.1993.s19">Berkovic et al 1993</xref>, <xref ref-type="bibr" rid="lafora.REF.minassian.2000b.341">Minassian et al 2000b</xref>].</p>
          <p>The course of the disease is characterized by increasing frequency and intractability of seizures. Status epilepticus with any of the previously mentioned seizure types is common. Cognitive decline becomes apparent at or soon after the onset of seizures. Dysarthria and ataxia appear early, spasticity late. Emotional disturbance and confusion are common in the early stages of the disease and are followed by dementia.</p>
          <p>By their mid-twenties, most affected individuals are in a vegetative state with continuous myoclonus and require tube feeding. Some maintain minimal interactions with the family such as a reflex-like smiling upon cajoling. Affected individuals who are not tube-fed aspirate frequently as a result of seizures; death from aspiration pneumonia is common.</p>
          <p>Most affected individuals die within ten years of onset, usually from status epilepticus or from complications related to nervous system degeneration [<xref ref-type="bibr" rid="lafora.REF.minassian.2002.199">Minassian 2002</xref>].</p>
        </sec>
        <sec id="lafora.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations are difficult to establish in LD because compound heterozygotes in different combinations are common [<xref ref-type="bibr" rid="lafora.REF.chan.2005.47">Chan et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>]. Variation by country in the care available for individuals with LD may in part influence longevity and disease complications.</p>
          <p>Within an ethnic group of individuals sharing the same pathogenic variant the phenotype can be highly variable [<xref ref-type="bibr" rid="lafora.REF.g_mezabad.2007.1011">G&#x000f3;mez-Abad et al 2007</xref>] or very similar [<xref ref-type="bibr" rid="lafora.REF.turnbull.2008.240">Turnbull et al 2008</xref>].</p>
          <p>Intra- and interfamilial variability in age at onset is considerable, suggesting that genetic factors other than the <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> pathogenic variants may influence the pathogenesis of LD [<xref ref-type="bibr" rid="lafora.REF.g_mezabad.2007.1011">G&#x000f3;mez-Abad et al 2007</xref>, <xref ref-type="bibr" rid="lafora.REF.lohi.2007.996">Lohi et al 2007</xref>]. The LD gene products laforin and malin are known to interact with a diverse set of proteins and variations in gene(s) that code for these interacting protein(s) could contribute to variations in phenotype [<xref ref-type="bibr" rid="lafora.REF.singh.2012.283">Singh &#x00026; Ganesh 2012</xref>]. It has indeed been demonstrated that a sequence variant in <italic toggle="yes">PPP1R3C</italic>, which codes for the protein PTG (protein targeting to glycogen), contributes to a milder course of LD [<xref ref-type="bibr" rid="lafora.REF.guerrero.2011.e21294">Guerrero et al 2011</xref>].</p>
          <p>To date, no correlations between phenotype and variant type (missense or truncating) or location of the pathogenic variant in the gene have been demonstrated</p>
          <list list-type="bullet">
            <list-item>
              <p>Although a sub-phenotype consisting of childhood-onset learning disorder followed by epilepsy and neurologic deterioration has been associated with either pathogenic variants in exon 1 of <italic toggle="yes">EPM2A</italic> [<xref ref-type="bibr" rid="lafora.REF.ganesh.2002a.1251">Ganesh et al 2002a</xref>, <xref ref-type="bibr" rid="lafora.REF.annesi.2004.294">Annesi et al 2004</xref>] or the <xref ref-type="table" rid="lafora.T.nhlrc1_pathogenic_variants_disc">p.Ile198Asn</xref> pathogenic variant located in an NHL protein-protein interaction domain of <italic toggle="yes">NHLRC1</italic> [<xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>], these findings need to be replicated, expanded, and studied further in order to understand their relationship to the underlying pathophysiologic processes.</p>
            </list-item>
            <list-item>
              <p>Individuals with pathogenic variants in <italic toggle="yes">NHLRC1</italic> appear to live longer than those with pathogenic variants in <italic toggle="yes">EPM2A</italic> [<xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2006.e48">Singh et al 2006</xref>]. This finding has been demonstrated repeatedly for persons with the <italic toggle="yes">NHLRC1</italic> pathogenic variant <xref ref-type="table" rid="lafora.T.nhlrc1_pathogenic_variants_disc">p.Asp146Asn</xref> [<xref ref-type="bibr" rid="lafora.REF.baykan.2005.1695">Baykan et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al 2006</xref>]. However, this does not apply to all persons with pathogenic variants in <italic toggle="yes">NHLRC1</italic>, as some may have extremely severe phenotypes [<xref ref-type="bibr" rid="lafora.REF.traor_.2009.319">Traor&#x000e9; et al 2009</xref>, <xref ref-type="bibr" rid="lafora.REF.brackmann.2011.475">Brackmann et al 2011</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="lafora.Nomenclature">
          <title>Nomenclature</title>
          <p>Lafora disease (LD) is also referred to as myoclonic epilepsy of Lafora or progressive myoclonic epilepsy type 2.</p>
          <p>The term progressive myoclonus epilepsy (PME) covers a large and varied group of diseases characterized by myoclonus, generalized tonic-clonic seizures, and progressive neurologic deterioration [<xref ref-type="bibr" rid="lafora.REF.berkovic.1986.296">Berkovic et al 1986</xref>].</p>
        </sec>
        <sec id="lafora.Prevalence">
          <title>Prevalence</title>
          <p>Exact prevalence figures for LD are not available.</p>
          <p>LD occurs worldwide. Although relatively rare in the non-consanguineous populations of the United States, Canada, China, and Japan, LD is relatively common in the Mediterranean basin of Spain, France, and Italy, in restricted regions of central Asia, India, Pakistan, northern Africa, and the Middle East, in ethnic isolates from the southern United States and Quebec, and in other parts of the world with a high rate of consanguinity [<xref ref-type="bibr" rid="lafora.REF.delgadoescueta.2001.129">Delgado-Escueta et al 2001</xref>].</p>
          <p>Within the Italian and Japanese populations, pathogenic variants in <italic toggle="yes">NHLRC1</italic> are more common than pathogenic variants in <italic toggle="yes">EPM2A</italic>. Conversely, <italic toggle="yes">EPM2A</italic> pathogenic variants are more common in the Spanish and French populations. Within the Indian and Arab populations the distribution of pathogenic variants in the two genes is more or less even [<xref ref-type="bibr" rid="lafora.REF.singh.2009.715">Singh &#x00026; Ganesh 2009</xref>, <xref ref-type="bibr" rid="lafora.REF.lesca.2010.1691">Lesca et al 2010</xref>].</p>
          <p>Note: LD has not been reported in Finland, where founder effects for a number of genetic disorders are common, and where EPM1 (<related-object link-type="booklink" source-id="gene" document-id="epm1" document-type="chapter">Unverricht-Lundborg disease</related-object>) has the highest prevalence [A Lehesjoki &#x00026; R K&#x000e4;lvi&#x000e4;inen, personal communication].</p>
        </sec>
      </sec>
      <sec id="lafora.Genetically_Related_Allelic_Disor">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic>.</p>
      </sec>
      <sec id="lafora.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Early-onset Lafora body disease</bold> is a newly recognized condition characterized by progressive myoclonus epilepsy and Lafora bodies [<xref ref-type="bibr" rid="lafora.REF.turnbull.2012.2684">Turnbull et al 2012</xref>]. In contrast to Lafora disease (LD), early-onset LD typically presents at around age five years. Symptoms include dysarthria, myoclonus, and ataxia, which can be confused with late infantile-variant neuronal ceroid lipofuscinosis. However, pathology reveals Lafora bodies instead of ceroid lipofuscinosis. The disease course of early-onset LD is much more protracted than either infantile neuronal ceroid lipofuscinosis or Lafora disease. Early-onset LD is caused by pathogenic variants in <italic toggle="yes">PRDM8</italic>.</p>
        <p><bold>Juvenile myoclonic epilepsy</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/254770">254770</ext-link>). Although the occurrence of myoclonus and generalized tonic-clonic seizures in adolescence may raise the possibility of juvenile myoclonic epilepsy, the persistence of EEG background slowing and cognitive deterioration should raise the suspicion of a more severe epilepsy syndrome, such as PME.</p>
        <p>Earlier age at onset, slower rate of disease progression, and absence of Lafora bodies on skin biopsy differentiates <related-object link-type="booklink" source-id="gene" document-id="epm1" document-type="chapter"><bold>Unverricht-Lundborg disease</bold></related-object> (EPM1) from Lafora disease (LD).</p>
        <p>Careful ophthalmologic examination, including electroretinography, is useful in addressing the possibilities of <related-object link-type="booklink" source-id="gene" document-id="ncl" document-type="chapter"><bold>neuronal ceroid-lipofuscinoses</bold></related-object> and <bold>sialidosis</bold>.</p>
        <p>Cerebrospinal fluid concentration of lactate and titers of measles antibody can be helpful in dismissing the possibility of <related-object link-type="booklink" source-id="gene" document-id="merrf" document-type="chapter"><bold>myoclonic epilepsy with ragged red fibers</bold></related-object> (MERRF) and <bold>subacute sclerosing panencephalitis</bold> (SSPE), respectively [<xref ref-type="bibr" rid="lafora.REF.minassian.2001.21">Minassian 2001</xref>, <xref ref-type="bibr" rid="lafora.REF.minassian.2002.199">Minassian 2002</xref>].</p>
        <p>Visual hallucinations, withdrawal, and cognitive decline raise concerns of <bold>schizophrenia</bold>, which becomes less likely with the onset of convulsions and the appearance of an epileptiform EEG.</p>
        <p>MRI excludes structural abnormalities, and posteriorly dominant irregular spike-wave discharges on EEG raise suspicion of LD.</p>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS254800">Epilepsy, progressive myoclonic: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="lafora.Management">
        <title>Management</title>
        <sec id="lafora.Evaluations_Following_Initial_Dia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Lafora disease (LD), the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical evaluation</p>
            </list-item>
            <list-item>
              <p>Evaluation of speech, walking, coordination, handwriting, school performance, and emotional status</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="lafora.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Antiepileptic drugs (AEDs) have a major effect against generalized seizures, sometimes controlling seizures for many months. Generalized seizures are rare in individuals who are treated, even years after disease onset.</p>
          <p><bold>Valproic acid</bold> is the traditional antiepileptic treatment for LD; because it is a broad-spectrum AED, it controls both the generalized tonic-clonic seizures and myoclonic jerks.</p>
          <p><bold>Clonazepam</bold> can be used as an adjunctive medication for control of myoclonus, as in other forms of PME, although the literature does not provide clear evidence for its effect on myoclonus in LD.</p>
          <p><bold>Zonisamide</bold> has had a significant effect on both seizures and myoclonus in a small number of individuals with <related-object link-type="booklink" source-id="gene" document-id="epm1" document-type="chapter">Unverricht-Lundborg disease</related-object> and Lafora disease.</p>
          <p>Both <bold>piracetam</bold> and <bold>levetiracetam</bold> have been effective, sustained, and well tolerated as add-on treatment for myoclonus in progressive myoclonus epilepsy (PME) [<xref ref-type="bibr" rid="lafora.REF.koskiniemi.1998.344">Koskiniemi et al 1998</xref>, <xref ref-type="bibr" rid="lafora.REF.genton.1999.49">Genton et al 1999</xref>, <xref ref-type="bibr" rid="lafora.REF.fedi.2001.781">Fedi et al 2001</xref>, <xref ref-type="bibr" rid="lafora.REF.crest.2004.640">Crest et al 2004</xref>]. Levetiracetam had a significant effect on myoclonus in two sisters with LD [<xref ref-type="bibr" rid="lafora.REF.boccella.2003.55">Boccella et al 2003</xref>]. <xref ref-type="bibr" rid="lafora.REF.lohi.2006.399">Lohi et al [2006]</xref> reported that levetiracetam exacerbated seizures while improving myoclonus in two persons with LD.</p>
        </sec>
        <sec id="lafora.Prevention_of_Secondary_Complicat">
          <title>Prevention of Secondary Complications</title>
          <p>Because the myoclonus associated with LD may be drug resistant, overmedication may be a risk in individuals with LD .</p>
          <p>Placement by percutaneous endoscopy of a gastrostomy tube for feeding can be helpful in decreasing the risk of aspiration pneumonia in individuals with advanced disease.</p>
        </sec>
        <sec id="lafora.Surveillance">
          <title>Surveillance</title>
          <p>Clinical and psychosocial evaluation should be performed at three- to six-month intervals throughout the teen years.</p>
        </sec>
        <sec id="lafora.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>As in other forms of progressive myoclonus epilepsies, the use of phenytoin should be avoided.</p>
          <p>Anecdotal reports describe possible exacerbation of myoclonus with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Carbamazepine [<xref ref-type="bibr" rid="lafora.REF.nanba.1999.664">Nanba &#x00026; Maegaki 1999</xref>]</p>
            </list-item>
            <list-item>
              <p>Oxcarbazepine [<xref ref-type="bibr" rid="lafora.REF.kaddurah.2006.289">Kaddurah &#x00026; Holmes 2006</xref>]</p>
            </list-item>
            <list-item>
              <p>Lamotrigine [<xref ref-type="bibr" rid="lafora.REF.cerminara.2004.373">Cerminara et al 2004</xref>, <xref ref-type="bibr" rid="lafora.REF.crespel.2005.762">Crespel et al 2005</xref>]</p>
            </list-item>
          </list>
        </sec>
        <sec id="lafora.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="lafora.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to evaluation of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="lafora.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Work in animal models has shown that glycogen synthesis is requisite for glycogen accumulation and Lafora body formation; such glycogen accumulation is pathogenic [<xref ref-type="bibr" rid="lafora.REF.turnbull.2011.e1002037">Turnbull et al 2011</xref>, <xref ref-type="bibr" rid="lafora.REF.pederson.2013.297">Pederson et al 2013</xref>, <xref ref-type="bibr" rid="lafora.REF.duran.2014.3147">Duran et al 2014</xref>, <xref ref-type="bibr" rid="lafora.REF.turnbull.2014.442">Turnbull et al 2014</xref>]. This suggests a therapeutic window for potential treatments using known and future small-molecule inhibitors of glycogen synthesis in individuals with LD.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="lafora.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="lafora.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Lafora disease (LD) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="lafora.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier of an <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> pathogenic variant is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Because of the early onset and rapid deterioration, individuals with LD typically do not reproduce.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of an <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> pathogenic variant; first cousins of the proband are at a 25% risk of being carriers.</p>
        </sec>
        <sec id="lafora.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> pathogenic variants in the family.</p>
          <p>Carrier testing is also possible for the reproductive partners of known carriers; however, absence of a detectable <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> pathogenic variant lowers the likelihood that the reproductive partner is a carrier but does not rule out this possibility.</p>
        </sec>
        <sec id="lafora.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="lafora.Prenatal_Testing_and_Preimplantat">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for LD are possible.</p>
        </sec>
      </sec>
      <sec id="lafora.Resources">
        <title>Resources</title>
      </sec>
      <sec id="lafora.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="lafora.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The mechanism by which pathogenic variants in either <italic toggle="yes">EPM2A</italic> or <italic toggle="yes">NHLRC1</italic> result in Lafora disease (LD) and the exact role of the Lafora bodies in the pathogenesis of LD have been the subject of intensive research efforts over the past few years.</p>
          <p>Pathology in LD consists of the progressive formation of polyglucosans (insoluble glucose polysaccharides that precipitate and aggregate into concretized masses called Lafora bodies) resulting in neurodegeneration. Lafora bodies form in neuronal perikarya and in neuronal short processes (mostly dendrites). Lafora bodies in the neuronal processes are much smaller but they massively outnumber Lafora bodies in the perikarya. Extraneurally, Lafora bodies also form in heart, liver, and skeletal muscle, but cause no symptoms in these organs [<xref ref-type="bibr" rid="lafora.REF.turnbull.2011.e1002037">Turnbull et al 2011</xref>].</p>
          <p>A normal glycogen molecule contains up to 55,000 glucose units, yet remains soluble because its glucose chains are short (13 units), each chain is a branch of another, and the whole molecule is a sphere, the surface of which is composed of the hydrophilic ends of chains [<xref ref-type="bibr" rid="lafora.REF.graham.2010.489">Graham et al 2010</xref>]. This unique organization allows mammalian cells to store large amounts of carbohydrate energy in a soluble, rapidly accessible form. Without branching, glucose polymers 13 units or longer are poorly soluble and tend to precipitate and crystallize [<xref ref-type="bibr" rid="lafora.REF.hejazi.2008.323">Hejazi et al 2008</xref>]. Polyglucosans are malformed glycogen molecules. They have very long chains, insufficient branches, and a resultant lack of spherical organization. They are more similar to plant amylopectin or starch than to glycogen, and like these plant carbohydrates they are insoluble, precipitate, and accumulate [<xref ref-type="bibr" rid="lafora.REF.minassian.2001.21">Minassian 2001</xref>]. It has been demonstrated that in plants, variants in the starch excess 4 gene (<italic toggle="yes">SEX4</italic>) result in the accumulation of amylopectin, similar to the way loss of laforin leads to the accumulation of polyglucosans with formation of Lafora bodies in humans [<xref ref-type="bibr" rid="lafora.REF.niittyl_.2006.11815">Niittyl&#x000e4; et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.gentry.2007.477">Gentry et al 2007</xref>, <xref ref-type="bibr" rid="lafora.REF.gentry.2009.628">Gentry et al 2009</xref>]. In plants, human laforin can rescue the <italic toggle="yes">SEX4</italic>-mutated phenotype [<xref ref-type="bibr" rid="lafora.REF.gentry.2007.477">Gentry et al 2007</xref>].</p>
          <p>Glycogen is synthesized through coordinated actions of glycogen synthase (GS) and glycogen branching enzyme, the former responsible for chain elongation, the latter for chain branching. Glycogen is digested by glycogen phosphorylase (GP) and glycogen debranching enzyme. PTG (protein targeting to glycogen) is an indirect activator of GS and an indirect inhibitor of both GP and glycogen phosphorylase kinase (GPK), the enzyme that activates GP. PTG performs this reciprocal activation of synthesis and inhibition of breakdown by binding the pleiotropic phosphatase PP1 through its C-terminus, binding glycogen, and through a common region in its N-terminus binding GS, GP, or GPK, thus targeting PP1 to each of the three enzymes. PP1 dephosphorylates each of the three enzymes, activating GS and inhibiting GP and GPK [<xref ref-type="bibr" rid="lafora.REF.turnbull.2011.e1002037">Turnbull et al 2011</xref>].</p>
          <p>Absence of laforin results in glycogen hyperphosphorylation, which disturbs the construction of glycogen, preventing its elaborate spherical architecture essential to solubility [<xref ref-type="bibr" rid="lafora.REF.worby.2006.30412">Worby et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.tagliabracci.2008.33816">Tagliabracci et al 2008</xref>, <xref ref-type="bibr" rid="lafora.REF.nitschke.2013.756">Nitschke et al 2013</xref>]. The malformed glycogen (polyglucosan) precipitates, aggregates, and accumulates into Lafora bodies (LB). Glycogen synthase (GS) is essential to glycogen synthesis, whether the final structure is normal or polyglucosan [<xref ref-type="bibr" rid="lafora.REF.tagliabracci.2008.33816">Tagliabracci et al 2008</xref>]. Glycogen accumulation has been shown to account for the neurodegeneration and functional consequences in LD mice, identifying the regulation of glycogen synthesis as a key target for the treatment of LD [<xref ref-type="bibr" rid="lafora.REF.duran.2014.3147">Duran et al 2014</xref>]. Treating LD through downregulation of GS has been shown effective in different mouse models. Genetically removing brain GS from laforin-lacking LD mice resulted in correction of the LD phenotype, including elimination of LB, neurodegeneration, and seizure predisposition [<xref ref-type="bibr" rid="lafora.REF.pederson.2013.297">Pederson et al 2013</xref>]. The same result was obtained through partial reduction of glycogen synthesis by genetically removing PTG, a protein that activates GS. This was shown effective in laforin-deficient LD mice [<xref ref-type="bibr" rid="lafora.REF.turnbull.2011.e1002037">Turnbull et al 2011</xref>] as well as in malin-deficient LD mice [<xref ref-type="bibr" rid="lafora.REF.worby.2008.4069">Worby et al 2008</xref>, <xref ref-type="bibr" rid="lafora.REF.turnbull.2014.442">Turnbull et al 2014</xref>].</p>
          <p>Malin has been suggested to regulate autophagy [<xref ref-type="bibr" rid="lafora.REF.criado.2012.1521">Criado et al 2012</xref>], the misfolded protein response [<xref ref-type="bibr" rid="lafora.REF.mittal.2007.753">Mittal et al 2007</xref>], microRNA silencing [<xref ref-type="bibr" rid="lafora.REF.singh.2012.1440">Singh et al 2012</xref>], Wnt signal transduction [<xref ref-type="bibr" rid="lafora.REF.sharma.2012.6830">Sharma et al 2012</xref>], and neuronatin-mediated endoplasmic reticulum stress [<xref ref-type="bibr" rid="lafora.REF.sharma.2013.9482">Sharma et al 2013</xref>], implying a possible complex causality in the EPM2B form of LD. Nevertheless, LD caused by mutation of <italic toggle="yes">EPM2B</italic> is as responsive to glycogen synthesis downregulation as is LD caused by mutation of <italic toggle="yes">EPM2A</italic> [<xref ref-type="bibr" rid="lafora.REF.turnbull.2014.442">Turnbull et al 2014</xref>].</p>
          <sec id="lafora.EPM2A">
            <title>
              <italic toggle="yes">EPM2A</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">EPM2A</italic> has four exons spanning 130 kb; they are alternatively spliced to form two major <italic toggle="yes">EPM2A</italic> transcripts [<xref ref-type="bibr" rid="lafora.REF.minassian.1998.171">Minassian et al 1998</xref>, <xref ref-type="bibr" rid="lafora.REF.serratosa.1999.345">Serratosa et al 1999</xref>, <xref ref-type="bibr" rid="lafora.REF.ganesh.2000.2251">Ganesh et al 2000</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezgarre.2000.946">G&#x000f3;mez-Garre et al 2000</xref>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005670.3">NM_005670.3</ext-link> represents the longer transcript and encodes the longer laforin isoform (a) of 331 amino acids. For a detailed summary of gene, transcript, and protein isoform information, see <related-object source-id="gene" document-id="lafora" object-id="lafora.molgen.TA">Table A</related-object>, <bold>Gene</bold> and <bold>Normal gene product</bold>.</p>
            <p><bold>Benign variants.</bold> Several benign variants in <italic toggle="yes">EPM2A</italic> have been described [<xref ref-type="bibr" rid="lafora.REF.g_mezgarre.2000.946">G&#x000f3;mez-Garre et al 2000</xref>, <xref ref-type="bibr" rid="lafora.REF.minassian.2000b.341">Minassian et al 2000b</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2005.347">Singh et al 2005</xref>]. Among these, 136G&#x0003e;C (<xref ref-type="table" rid="lafora.T.nhlrc1_pathogenic_variants_disc">p.Ala46Pro</xref>) is specific to the Japanese and Chinese populations [<xref ref-type="bibr" rid="lafora.REF.ganesh.2001.281">Ganesh et al 2001</xref>].</p>
            <p><bold>Variants of uncertain significance.</bold> The <xref ref-type="table" rid="lafora.T.nhlrc1_pathogenic_variants_disc">p.Gln55Lys</xref> substitution in <italic toggle="yes">EPM2A</italic> was found in two affected persons who were also heterozygous for a large deletion in <italic toggle="yes">NHLRC1</italic> as well as in seven of 500 individuals without LD and in a person with adult-onset disease, also in the heterozygous state. To date, it remains unclear whether this change constitutes a rare benign SNP of no consequence, whether it may cause LD when homozygous, or whether it could predispose to <italic toggle="yes">NHLRC1</italic> deletion in certain situations [<xref ref-type="bibr" rid="lafora.REF.lohi.2007.996">Lohi et al 2007</xref>].</p>
            <p><bold>Pathogenic variants.</bold> To date, more than 60 different pathogenic variants in <italic toggle="yes">EPM2A</italic> have been reported in more than 100 families [<xref ref-type="bibr" rid="lafora.REF.minassian.1998.171">Minassian et al 1998</xref>, <xref ref-type="bibr" rid="lafora.REF.serratosa.1999.345">Serratosa et al 1999</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezgarre.2000.946">G&#x000f3;mez-Garre et al 2000</xref>, <xref ref-type="bibr" rid="lafora.REF.minassian.2000a.488">Minassian et al 2000a</xref>, <xref ref-type="bibr" rid="lafora.REF.minassian.2000b.341">Minassian et al 2000b</xref>, <xref ref-type="bibr" rid="lafora.REF.ganesh.2002a.1251">Ganesh et al 2002a</xref>, <xref ref-type="bibr" rid="lafora.REF.ki.2003.51">Ki et al 2003</xref>, <xref ref-type="bibr" rid="lafora.REF.annesi.2004.294">Annesi et al 2004</xref>, <xref ref-type="bibr" rid="lafora.REF.ianzano.2004.170">Ianzano et al 2004</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2005.347">Singh et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.lohi.2006.399">Lohi et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2009.715">Singh &#x00026; Ganesh 2009</xref>, <xref ref-type="bibr" rid="lafora.REF.lesca.2010.1691">Lesca et al 2010</xref>, <xref ref-type="bibr" rid="lafora.REF.harirchian.2011.374">Harirchian et al 2011</xref>, <xref ref-type="bibr" rid="lafora.REF.khiari.2011.136">Khiari et al 2011</xref>]. Nonsense and missense single-nucleotide variants accounted for 61%, frameshift variants for 29%, and large deletions for 10% of the total. One splice site variant has been reported for <italic toggle="yes">EPM2A</italic> [<xref ref-type="bibr" rid="lafora.REF.lesca.2010.1691">Lesca et al 2010</xref>]. An overview of the different pathogenic variants can be found in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://projects.tcag.ca/lafora/">Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism Database</ext-link> [<xref ref-type="bibr" rid="lafora.REF.ianzano.2005.397">Ianzano et al 2005</xref>].</p>
            <p>Of all the types of pathogenic variants in <italic toggle="yes">EPM2A</italic> described to date, 45% represent missense variants; all the known missense variants target either the carbohydrate-binding domain (CBD) or the dual-specificity phosphatase domain (DSPD) of laforin [<xref ref-type="bibr" rid="lafora.REF.ganesh.2006.1">Ganesh et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2009.715">Singh &#x00026; Ganesh 2009</xref>, <xref ref-type="bibr" rid="lafora.REF.khiari.2011.136">Khiari et al 2011</xref>].</p>
            <p>Except for the larger deletions, all the pathogenic variants are distributed evenly across <italic toggle="yes">EPM2A</italic>. The only exception is the high prevalence of the nonsense c.721C&#x0003e;T variant, the so-called &#x02018;Spanish&#x02019; pathogenic variant, in over 20 families. Its high prevalence is the result of both a founder effect and recurrent events [<xref ref-type="bibr" rid="lafora.REF.minassian.1998.171">Minassian et al 1998</xref>, <xref ref-type="bibr" rid="lafora.REF.serratosa.1999.345">Serratosa et al 1999</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezgarre.2000.946">G&#x000f3;mez-Garre et al 2000</xref>, <xref ref-type="bibr" rid="lafora.REF.ganesh.2002b.1263">Ganesh et al 2002b</xref>].</p>
            <table-wrap id="lafora.T.epm2a_variants_discussed_in_thi" orientation="portrait" position="anchor">
              <label>Table 3. </label>
              <caption>
                <p><italic toggle="yes">EPM2A</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                    <th id="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>Benign</bold>
                    </td>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">136G&#x0003e;C</td>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala46Pro</td>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005670.3">NM_005670.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_005661.1">NP_005661.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>Of uncertain significance</bold>
                    </td>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.163C&#x0003e;A</td>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln55Lys</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>Pathogenic</bold>
                    </td>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.721C&#x0003e;T</td>
                    <td headers="hd_h_lafora.T.epm2a_variants_discussed_in_thi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg241Ter</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">EPM2A</italic> is known to encode two distinct proteins by differential splicing; a phosphatase active cytoplasmic isoform (a) (laforin, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_005661.1">NP_005661.1</ext-link>) and a phosphatase inactive nuclear isoform (b) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001018051.1">NP_001018051.1</ext-link>). Both isoforms of the laforin protein have unique C termini [<xref ref-type="bibr" rid="lafora.REF.ganesh.2002c.1134">Ganesh et al 2002c</xref>, <xref ref-type="bibr" rid="lafora.REF.ianzano.2004.170">Ianzano et al 2004</xref>]. The carboxyl terminal of isoform (b) targets laforin to the nucleus, a feature that is not shared by longer laforin isoform (a). <xref ref-type="bibr" rid="lafora.REF.ianzano.2004.170">Ianzano et al [2004]</xref> demonstrated that disturbances in the physiologic functions of laforin isoform (a) underlie the pathogenesis of LD, and isoform (b) cannot functionally substitute for laforin isoform (a). The common segment of the laforin isoforms consists of a carbohydrate-binding module and a dual-specificity protein phosphatase domain [<xref ref-type="bibr" rid="lafora.REF.ganesh.2000.2251">Ganesh et al 2000</xref>].</p>
            <p>Dubey et al identified three additional <italic toggle="yes">EPM2A</italic> splice variants with potential to code for five distinct proteins in alternate reading frames. The novel isoforms, when ectopically expressed in cell lines, show distinct subcellular localization, interact with and serve as substrates of malin (protein product of <italic toggle="yes">NHLRC1</italic>). Alternative splicing could possibly be one of the mechanisms by which <italic toggle="yes">EPM2A</italic> regulates the cellular functions of the proteins it codes for [<xref ref-type="bibr" rid="lafora.REF.dubey.2012.36">Dubey et al 2012</xref>].</p>
            <p>Laforin contains an N-terminal carbohydrate-binding domain (CBD), encoded mainly by exon 1, and a dual-specificity phosphatase domain (DSPD) spanning exons 3 and 4 [<xref ref-type="bibr" rid="lafora.REF.minassian.2000b.341">Minassian et al 2000b</xref>, <xref ref-type="bibr" rid="lafora.REF.ganesh.2002b.1263">Ganesh et al 2002b</xref>].</p>
            <p>Laforin is conserved in all vertebrates; while it has been lost in the vast majority of lower organisms, it is an ancient protein that is conserved in a subset of protists and invertebrates that have undergone slower rates of molecular evolution and/or metabolize a carbohydrate similar to Lafora bodies. The laforin protein holds a unique place in evolutionary biology and has yielded insights into glucan metabolism and the molecular etiology of Lafora disease [<xref ref-type="bibr" rid="lafora.REF.gentry.2009.138">Gentry &#x00026; Pace 2009</xref>].</p>
            <p><bold>Abnormal gene product.</bold> Nonsense variants, insertions, and deletions in <italic toggle="yes">EPM2A</italic> are predicted to be functionally 'null' and to have lost phosphatase activity. Missense variants in <italic toggle="yes">EPM2A</italic> also result in a lack of phosphatase activity in vitro, resulting in a 'null' effect [<xref ref-type="bibr" rid="lafora.REF.fern_ndezs_nchez.2003.3161">Fern&#x000e1;ndez-S&#x000e1;nchez et al 2003</xref>, <xref ref-type="bibr" rid="lafora.REF.ganesh.2006.1">Ganesh et al 2006</xref>]. Loss of phosphatase activity is not restricted to pathogenic variants located in the DSPD; it has also been observed for pathogenic variants affecting the CBD of <italic toggle="yes">EPM2A</italic> [<xref ref-type="bibr" rid="lafora.REF.wang.2002.2377">Wang et al 2002</xref>, <xref ref-type="bibr" rid="lafora.REF.fern_ndezs_nchez.2003.3161">Fern&#x000e1;ndez-S&#x000e1;nchez et al 2003</xref>]. It is likely that the missense variants affect proper folding of the laforin protein, as illustrated by transfection experiments overexpressing missense mutants, which resulted in ubiquitin-positive cytoplasmic aggregates, suggesting that they were folding mutants destined for degradation [<xref ref-type="bibr" rid="lafora.REF.ganesh.2000.2251">Ganesh et al 2000</xref>, <xref ref-type="bibr" rid="lafora.REF.ganesh.2002a.1251">Ganesh et al 2002a</xref>]. Missense variants also affect the subcellular localization of laforin [<xref ref-type="bibr" rid="lafora.REF.ganesh.2002a.1251">Ganesh et al 2002a</xref>, <xref ref-type="bibr" rid="lafora.REF.mittal.2007.753">Mittal et al 2007</xref>] and disrupt the interaction of laforin with R5 and malin (protein product of <italic toggle="yes">NHLRC1</italic>) proteins that interact with laforin in vivo [<xref ref-type="bibr" rid="lafora.REF.fern_ndezs_nchez.2003.3161">Fern&#x000e1;ndez-S&#x000e1;nchez et al 2003</xref>, <xref ref-type="bibr" rid="lafora.REF.gentry.2005.8501">Gentry et al 2005</xref>]. It is evident that not all aspects of the protein function have been tested for each missense variant, and that sensitive assays for checking the effect of pathogenic variants on the proteins function are yet to be developed [<xref ref-type="bibr" rid="lafora.REF.singh.2009.715">Singh &#x00026; Ganesh 2009</xref>].</p>
          </sec>
          <sec id="lafora.NHLRC1_EPM2B">
            <title>
              <italic toggle="yes">NHLRC1 (EPM2B)</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">NHLRC1</italic> is a single-exon gene spanning 1,188 base pairs that has all of the proposed features of the consensus sequence of a eukaryotic translational initiation site at its 5' end and two putative polyadenylation signals at its 3' end. Northern blot analysis indicates the presence of <italic toggle="yes">NHLRC1</italic> as two transcripts of 1.5 kb and 2.4 kb in all tissues examined, including specific subregions of the brain [<xref ref-type="bibr" rid="lafora.REF.chan.2003b.125">Chan et al 2003b</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="lafora" object-id="lafora.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Benign variants.</bold> Six benign variants have been reported [<xref ref-type="bibr" rid="lafora.REF.chan.2003b.125">Chan et al 2003b</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2005.347">Singh et al 2005</xref>].</p>
            <p><bold>Pathogenic variants.</bold> To date, more than 60 pathogenic variants have been reported in more than 125 families. The majority are missense variants, although insertions, deletions, and nonsense variants have also been found [<xref ref-type="bibr" rid="lafora.REF.chan.2003b.125">Chan et al 2003b</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2005.347">Singh et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2006.e48">Singh et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.lohi.2007.996">Lohi et al 2007</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2009.715">Singh &#x00026; Ganesh 2009</xref>, <xref ref-type="bibr" rid="lafora.REF.traor_.2009.319">Traor&#x000e9; et al 2009</xref>, <xref ref-type="bibr" rid="lafora.REF.lesca.2010.1691">Lesca et al 2010</xref>, <xref ref-type="bibr" rid="lafora.REF.couarch.2011.915">Couarch et al 2011</xref>]. A heterozygous deletion of the entire <italic toggle="yes">NHLRC1</italic> gene has been reported in an Italian and a Serbian family [<xref ref-type="bibr" rid="lafora.REF.lohi.2007.996">Lohi et al 2007</xref>]. An overview of pathogenic alleles in <italic toggle="yes">NHLRC1</italic> is available in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://projects.tcag.ca/lafora/">Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism Database</ext-link>.</p>
            <list list-type="bullet">
              <list-item>
                <p>The missense variant c.205C&#x0003e;G, affecting the RING finger domain, is the most common missense variant in <italic toggle="yes">NHLRC1</italic> (&#x0003e;30 families). It is present in all affected individuals of Portuguese origin and has been reported repeatedly in affected persons of Italian, French, and Spanish heritage [<xref ref-type="bibr" rid="lafora.REF.chan.2003a.671">Chan et al 2003a</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al 2006</xref>, <xref ref-type="bibr" rid="lafora.REF.lesca.2010.1691">Lesca et al 2010</xref>]. The high prevalence of this pathogenic variant is also explained both by founder effect and recurrent mutation events [<xref ref-type="bibr" rid="lafora.REF.chan.2003a.671">Chan et al 2003a</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.franceschetti.2006.640">Franceschetti et al 2006</xref>].</p>
              </list-item>
              <list-item>
                <p>The c.468_469delAG pathogenic variant, involving the removal of two bases in the coding region, is the second most common pathogenic variant in <italic toggle="yes">NHLRC1</italic> and is by far the most common deletion (25 families). It has been identified in 14 individuals belonging to the same genetic isolate of tribal Oman. All shared a common haplotype, suggesting a founder effect [<xref ref-type="bibr" rid="lafora.REF.turnbull.2008.240">Turnbull et al 2008</xref>].</p>
              </list-item>
              <list-item>
                <p>Note: Whereas c.205C&#x0003e;G pathogenic variant is common in affected persons of Italian and Spanish heritage, both the c.205C&#x0003e;G and c.468_469delAG pathogenic variants have been identified in different ethnic groups, suggesting a recurrent mutation event; these two sites represent hot spots for <italic toggle="yes">NHLRC1</italic> pathogenic variants [<xref ref-type="bibr" rid="lafora.REF.ganesh.2006.1">Ganesh et al 2006</xref>].</p>
              </list-item>
              <list-item>
                <p>Missense pathogenic variant c.76T&#x0003e;A is prevalent in French-Canadian ethnic isolates [<xref ref-type="bibr" rid="lafora.REF.chan.2003a.671">Chan et al 2003a</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2006.e48">Singh et al 2006</xref>] and the shared chromosome 6p22 haplotype of these pedigrees suggested a founder effect [<xref ref-type="bibr" rid="lafora.REF.chan.2003a.671">Chan et al 2003a</xref>]. To date, all but one French-Canadian individual were homozygous for the c.76T&#x0003e;A pathogenic variant. This individual was heterozygous for two other <italic toggle="yes">NHLRC1</italic> pathogenic variants, but he was known to also have distant German and other European ancestry [<xref ref-type="bibr" rid="lafora.REF.chan.2003a.671">Chan et al 2003a</xref>]. To date, this pathogenic variant has not been detected in non-French-Canadian families.</p>
              </list-item>
            </list>
            <table-wrap id="lafora.T.nhlrc1_pathogenic_variants_disc" orientation="portrait" position="anchor">
              <label>Table 4. </label>
              <caption>
                <p><italic toggle="yes">NHLRC1</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.76T&#x0003e;A&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys26Ser</td>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_198586.2">NM_198586.2</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_940988.2">NP_940988.2</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.205C&#x0003e;G&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro69Ala</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.436G&#x0003e;A</td>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp146Asn</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.593T&#x0003e;A</td>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile198Asn</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.468_469delAG&#x000a0;<sup>1</sup></td>
                    <td headers="hd_h_lafora.T.nhlrc1_pathogenic_variants_disc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly158ArgfsTer17</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="lafora.TF.4.1">
                  <label>1. </label>
                  <p>Details in <bold>Pathogenic variants</bold></p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">NHLRC1</italic> encodes E3 ubiquitin-protein ligase NHLRC1 (also known as malin), a 395-amino acid protein. Malin contains a zinc finger of the RING type and six NHL-repeat protein-protein interaction domains [<xref ref-type="bibr" rid="lafora.REF.chan.2003b.125">Chan et al 2003b</xref>]. The presence of a RING finger predicts an E3 ubiquitin ligase function [<xref ref-type="bibr" rid="lafora.REF.freemont.2000.r84">Freemont 2000</xref>]. Malin colocalizes with laforin in the endoplasmic reticulum [<xref ref-type="bibr" rid="lafora.REF.mittal.2007.753">Mittal et al 2007</xref>]. Laforin and malin interact with misfolded proteins and promote their degradation through the ubiquitin-proteasome system [<xref ref-type="bibr" rid="lafora.REF.garyali.2009.688">Garyali et al 2009</xref>]. Malin is a single subunit E3 ubiquitin ligase involved in the ubiquitin-mediated proteolysis cascade [<xref ref-type="bibr" rid="lafora.REF.gentry.2005.8501">Gentry et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.lohi.2005.2727">Lohi et al 2005</xref>]. Malin also interacts with and ubiquitinates laforin, leading to its degradation [<xref ref-type="bibr" rid="lafora.REF.gentry.2005.8501">Gentry et al 2005</xref>]. Thus, one of the critical functions of malin is to regulate the cellular concentration of laforin by ubiquitin-mediated degradation [<xref ref-type="bibr" rid="lafora.REF.gentry.2005.8501">Gentry et al 2005</xref>].</p>
            <p><bold>Abnormal gene product.</bold> See <xref ref-type="bibr" rid="lafora.REF.ganesh.2006.1">Ganesh et al [2006]</xref>. Nearly all pathogenic variants in <italic toggle="yes">NHLRC1</italic> are predicted to result in the loss of function of malin [<xref ref-type="bibr" rid="lafora.REF.chan.2003b.125">Chan et al 2003b</xref>, <xref ref-type="bibr" rid="lafora.REF.g_mezabad.2005.982">G&#x000f3;mez-Abad et al 2005</xref>, <xref ref-type="bibr" rid="lafora.REF.singh.2005.347">Singh et al 2005</xref>]. Pathogenic missense variants in <italic toggle="yes">NHLRC1</italic> associated with LD disrupt a critical function of malin in regulating the cellular concentration of laforin by ubiquitin-mediated degradation [<xref ref-type="bibr" rid="lafora.REF.gentry.2005.8501">Gentry et al 2005</xref>].</p>
            <p>Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="lafora-animalModels.pdf" content-type="local-data">here</inline-supplementary-material> for more information on animal models of Lafora disease.</p>
          </sec>
        </sec>
      </sec>
      <sec id="lafora.References">
        <title>References</title>
        <sec id="lafora.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="lafora.Literature_Cited.reflist0">
            <ref id="lafora.REF.altindag.2009.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Altindag</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kara</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baykan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terzibasioglu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sencer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onat</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sirvanci</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>MR spectroscopy findings in Lafora disease.</article-title>
                <source>J Neuroimaging</source>
                <volume>19</volume>
                <fpage>359</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">19040628</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.andrade.2003.1611">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andrade</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minett</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teive</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohlega</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Skin biopsy in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls.</article-title>
                <source>Neurology</source>
                <volume>61</volume>
                <fpage>1611</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">14663053</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.annesi.2004.294">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Annesi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sofia</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambardella</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Candiano</surname>
                    <given-names>IC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spadafora</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Annesi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutuli</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marco</surname>
                    <given-names>EV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Civitelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrideo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarantino</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barone</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zappia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quattrone</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A novel exon 1 mutation in a patient with atypical lafora progressive myoclonus epilepsy seen as childhood-onset cognitive deficit.</article-title>
                <source>Epilepsia</source>
                <volume>45</volume>
                <fpage>294</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15009235</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.baykan.2005.1695">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baykan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Striano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gianotti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bebek</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gennaro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurses</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Late-onset and slow-progressing Lafora disease in four siblings with EPM2B mutation.</article-title>
                <source>Epilepsia</source>
                <volume>46</volume>
                <fpage>1695</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16190947</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.berkovic.1986.296">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>LS</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Progressive myoclonus epilepsies: specific causes and diagnosis.</article-title>
                <source>N Engl J Med</source>
                <volume>315</volume>
                <fpage>296</fpage>
                <lpage>305</lpage>
                <pub-id pub-id-type="pmid">3088452</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.berkovic.1993.s19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cochius</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Progressive myoclonus epilepsies: clinical and genetic aspects.</article-title>
                <source>Epilepsia.</source>
                <volume>34</volume>
                <supplement>Suppl 3</supplement>
                <fpage>S19</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">8500430</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.boccella.2003.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boccella</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Striano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbieri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarappa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vacca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Falco</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Striano</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters.</article-title>
                <source>Clin Neurol Neurosurg</source>
                <volume>106</volume>
                <fpage>55</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14643920</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.brackmann.2011.475">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brackmann</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiefer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agaimy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gencik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trollmann</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Rapidly progressive phenotype of Lafora disease associated with a novel NHLRC1 mutation.</article-title>
                <source>Pediatr Neurol</source>
                <volume>44</volume>
                <fpage>475</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21555062</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.canafoglia.2010.232">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Canafoglia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visani</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anversa</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panzica</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gennaro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease.</article-title>
                <source>Epilepsy Res</source>
                <volume>89</volume>
                <fpage>232</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20117916</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.carpenter.1981.1564">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpati</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1981</year>
                <article-title>Sweat gland duct cells in Lafora disease: diagnosis by skin biopsy.</article-title>
                <source>Neurology</source>
                <volume>31</volume>
                <fpage>1564</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">6796905</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.carpenter.1974.531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacob</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1974</year>
                <article-title>Lafora's disease: peroxisomal storage in skeletal muscle.</article-title>
                <source>Neurology</source>
                <volume>24</volume>
                <fpage>531</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">4220225</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.cerminara.2004.373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cerminara</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montanaro</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curatolo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seri</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy.</article-title>
                <source>Neurology</source>
                <volume>63</volume>
                <fpage>373</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15277643</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.chan.2005.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrade</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B.</article-title>
                <source>Adv Neurol</source>
                <volume>95</volume>
                <fpage>47</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">15508913</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.chan.2003a.671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bulman</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paterson</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2003a</year>
                <article-title>Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22.</article-title>
                <source>J Med Genet</source>
                <volume>40</volume>
                <fpage>671</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12960212</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.chan.2004.565">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Omer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridges</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus.</article-title>
                <source>Neurology</source>
                <volume>63</volume>
                <fpage>565</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15304597</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.chan.2003b.125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munteanu</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christopoulos</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avanzini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jovic</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohlega</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                </person-group>
                <year>2003b</year>
                <article-title>Mutations in NHLRC1 cause progressive myoclonus epilepsy.</article-title>
                <source>Nat Genet</source>
                <volume>35</volume>
                <fpage>125</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12958597</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.couarch.2011.915">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Couarch</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vernia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gourfinkel-An</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gataullina</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fedirko</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trouillard</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Depienne</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dulac</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steschenko</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leguern</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baulac</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.</article-title>
                <source>J Mol Med (Berl)</source>
                <year>2011</year>
                <volume>89</volume>
                <fpage>915</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">21505799</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.crespel.2005.762">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Crespel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berramdane</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coubes</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monicard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldy-Moulinier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelisse</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.</article-title>
                <source>Neurology</source>
                <volume>65</volume>
                <fpage>762</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16157917</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.crest.2004.640">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Crest</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leguern</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adam</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baulac</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients.</article-title>
                <source>Neurology</source>
                <volume>62</volume>
                <fpage>640</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">14981187</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.criado.2012.1521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Criado</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguado</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gayarre</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran-Trio</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Cabrero</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vernia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>San Mill&#x000e1;n</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heredia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rom&#x000e1;-Mateo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mouron</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Juana-L&#x000f3;pez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dom&#x000ed;nguez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navarro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bovolenta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knecht</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez de Cordoba</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.</article-title>
                <source>Hum Mol Genet</source>
                <volume>21</volume>
                <fpage>1521</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">22186026</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.delgadoescueta.2001.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Advances in the genetics of progressive myoclonus epilepsy.</article-title>
                <source>Am J Med Genet</source>
                <volume>106</volume>
                <fpage>129</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">11579433</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.drury.1993.102">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Drury</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaivas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abou-Khalil</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beydoun</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Biopsy results in a kindred with Lafora disease.</article-title>
                <source>Arch Neurol</source>
                <volume>50</volume>
                <fpage>102</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">8418793</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.dubey.2012.36">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dubey</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parihar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.</article-title>
                <source>Genomics</source>
                <volume>99</volume>
                <fpage>36</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">22036712</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.duran.2014.3147">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Rocha</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Garc&#x000ed;a</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guinovart</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease.</article-title>
                <source>Hum Mol Genet</source>
                <volume>23</volume>
                <fpage>3147</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">24452334</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.fedi.2001.781">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fedi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reutens</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubeau</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Agostino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy.</article-title>
                <source>Arch Neurol</source>
                <volume>58</volume>
                <fpage>781</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11346373</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.fern_ndezs_nchez.2003.3161">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez-S&#x000e1;nchez</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Criado-Garcia</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heath</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Fojeda</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medrano-Fernandez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez de Cordoba</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.</article-title>
                <source>Hum Mol Genet</source>
                <volume>12</volume>
                <fpage>3161</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">14532330</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.franceschetti.2006.640">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambardella</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canafoglia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Striano</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lohi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gennaro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veggiotti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sofia</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biondi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Striano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gellera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Annesi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Civitelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocca</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quattrone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avanzini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Clinical and genetic findings in 26 Italian patients with Lafora disease.</article-title>
                <source>Epilepsia</source>
                <volume>47</volume>
                <fpage>640</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">16529633</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.freemont.2000.r84">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Freemont</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>RING for destruction?</article-title>
                <source>Curr Biol</source>
                <volume>10</volume>
                <fpage>R84</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10662664</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ganesh.2000.2251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agarwala</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akagi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Usui</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashikawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.</article-title>
                <source>Hum Mol Genet</source>
                <volume>9</volume>
                <fpage>2251</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">11001928</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ganesh.2002a.1251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avila</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Machado-Salas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoshii</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akagi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agarwala</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bai</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishihara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashikawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itohara</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornford</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2002a</year>
                <volume>11</volume>
                <fpage>1251</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">12019206</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ganesh.2002b.1263">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francheschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riggio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avanzini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabinowicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bohlega</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alonso</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomson</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochoa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prado</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medina</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2002b</year>
                <article-title>Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.</article-title>
                <source>Hum Mol Genet</source>
                <volume>11</volume>
                <fpage>1263</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">12019207</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ganesh.2006.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mittal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubey</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy.</article-title>
                <source>J Hum Genet</source>
                <volume>51</volume>
                <fpage>1</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16311711</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ganesh.2001.281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchiyama</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moriyama</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirose</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.</article-title>
                <source>Mol Cell Probes</source>
                <volume>15</volume>
                <fpage>281</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11735300</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ganesh.2002c.1134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2002c</year>
                <article-title>Alternative splicing modulates subcellular localization of laforin.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>291</volume>
                <fpage>1134</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11883934</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.garyali.2009.688">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garyali</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siwach</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mittal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sengupta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parihar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.</article-title>
                <source>Hum Mol Genet</source>
                <volume>18</volume>
                <fpage>688</fpage>
                <lpage>700</lpage>
                <pub-id pub-id-type="pmid">19036738</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.genton.1999.49">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Genton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerrini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remy</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Piracetam in the treatment of cortical myoclonus.</article-title>
                <source>Pharmacopsychiatry.</source>
                <volume>32</volume>
                <supplement>Suppl 1</supplement>
                <fpage>49</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">10338109</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.gentry.2009.628">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gentry</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Worby</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Lafora disease: insights into neurodegeneration from plant metabolism.</article-title>
                <source>Trends Biochem Sci</source>
                <volume>34</volume>
                <fpage>628</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">19818631</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.gentry.2007.477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gentry</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dowen</surname>
                    <given-names>RH</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Worby</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mattoo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ecker</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease.</article-title>
                <source>J Cell Biol</source>
                <volume>178</volume>
                <fpage>477</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">17646401</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.gentry.2009.138">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gentry</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pace</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Conservation of the glucan phosphatase laforin is linked to rates of molecular evolution and the glucan metabolism of the organism.</article-title>
                <source>BMC Evol Biol</source>
                <volume>9</volume>
                <fpage>138</fpage>
                <pub-id pub-id-type="pmid">19545434</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.gentry.2005.8501">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gentry</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Worby</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>102</volume>
                <fpage>8501</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15930137</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.g_mezabad.2007.1011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Abad</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Afawi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korczyn</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misk</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shalev</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiegel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerman-Sagie</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lev</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kron</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation.</article-title>
                <source>Epilepsia</source>
                <volume>48</volume>
                <fpage>1011</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17509003</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.g_mezabad.2005.982">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Abad</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez-Delicado</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saygi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michelucci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassinari</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez de Cordoba</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Lafora disease due to EPM2B mutations: a clinical and genetic study.</article-title>
                <source>Neurology</source>
                <volume>64</volume>
                <fpage>982</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15781812</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.g_mezgarre.2000.946">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez De Cordoba</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>8</volume>
                <fpage>946</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11175283</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.graham.2010.489">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The regulation of muscle glycogen: the granule and its proteins.</article-title>
                <source>Acta Physiol (Oxf)</source>
                <volume>199</volume>
                <fpage>489</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">20353490</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.guerrero.2011.e21294">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guerrero</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vernia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abreu-Rodr&#x000ed;guez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almaraz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Hoyos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michelucci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassinari</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riguzzi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nobile</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A PTG variant contributes to a milder phenotype in Lafora disease.</article-title>
                <source>PLoS One</source>
                <volume>6</volume>
                <fpage>e21294</fpage>
                <pub-id pub-id-type="pmid">21738631</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.harirchian.2011.374">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harirchian</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shandiz</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahsiah</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Lafora disease: A case report, pathologic and genetic study.</article-title>
                <source>Indian J Pathol Microbiol</source>
                <volume>54</volume>
                <fpage>374</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21623095</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.hejazi.2008.323">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hejazi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fettke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haebel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paris</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frohberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steup</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ritte</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Glucan, water dikinase phosphorylates crystalline maltodextrins and thereby initiates solubilization.</article-title>
                <source>Plant J</source>
                <volume>55</volume>
                <fpage>323</fpage>
                <lpage>334</lpage>
                <pub-id pub-id-type="pmid">18419779</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ianzano.2004.170">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>XC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torrado</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.</article-title>
                <source>Hum Mutat</source>
                <volume>23</volume>
                <fpage>170</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">14722920</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ianzano.2005.397">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>XC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lohi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes.</article-title>
                <source>Hum Mutat</source>
                <volume>26</volume>
                <fpage>397</fpage>
                <pub-id pub-id-type="pmid">16134145</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.kaddurah.2006.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaddurah</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>GL</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Possible precipitation of myoclonic seizures with oxcarbazepine.</article-title>
                <source>Epilepsy Behav</source>
                <volume>8</volume>
                <fpage>289</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">16356781</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.kecmanovi_.2013.170">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kecmanovi&#x00107;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jovi&#x00107;</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuki&#x00107;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keckarevi&#x00107;-Markovi&#x00107;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keckarevi&#x00107;</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanovi&#x00107;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romac</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Lafora disease: severe phenotype associated with homozygous deletion of the NHLRC1 gene.</article-title>
                <source>J Neurol Sci</source>
                <volume>325</volume>
                <fpage>170</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">23317923</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.khiari.2011.136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khiari</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malafosse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mrabet</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A novel exon 3 mutation in a Tunisian patient with Lafora's disease.</article-title>
                <source>J Neurol Sci</source>
                <volume>304</volume>
                <fpage>136</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21371719</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.ki.2003.51">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ki</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kong</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seo</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hong</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.</article-title>
                <source>J Hum Genet</source>
                <volume>48</volume>
                <fpage>51</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12560877</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.koskiniemi.1998.344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koskiniemi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Vleymen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakamies</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamusuo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taalas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>64</volume>
                <fpage>344</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9527146</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.lesca.2010.1691">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boutry-Kryza</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Toffol</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steschenko</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemesle-Martin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maillard</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foletti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudolf</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nielsen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogvi-Hansen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thauvin-Robinet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M'Rabet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ville</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szepetowski</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raffo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirsch</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryvlin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calender</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genton</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease.</article-title>
                <source>Epilepsia.</source>
                <year>2010</year>
                <volume>51</volume>
                <fpage>1691</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20738377</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.lohi.2006.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lohi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>On the road to tractability: the current biochemical understanding of progressive myoclonus epilepsies.</article-title>
                <source>Adv Neurol</source>
                <volume>97</volume>
                <fpage>399</fpage>
                <lpage>415</lpage>
                <pub-id pub-id-type="pmid">16383151</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.lohi.2005.2727">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lohi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>XC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.</article-title>
                <source>Hum Mol Genet</source>
                <volume>14</volume>
                <fpage>2727</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">16115820</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.lohi.2007.996">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lohi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>XC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pullenayegum</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yahyaoui</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mikati</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinn</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franceschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls.</article-title>
                <source>Neurology</source>
                <volume>68</volume>
                <fpage>996</fpage>
                <lpage>1001</lpage>
                <pub-id pub-id-type="pmid">17389303</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.minassian.2001.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Lafora's disease: towards a clinical, pathologic, and molecular synthesis.</article-title>
                <source>Pediatr Neurol</source>
                <volume>25</volume>
                <fpage>21</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11483392</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.minassian.2002.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease.</article-title>
                <source>Adv Neurol</source>
                <volume>89</volume>
                <fpage>199</fpage>
                <lpage>210</lpage>
                <pub-id pub-id-type="pmid">11968446</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.minassian.2000a.488">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                </person-group>
                <year>2000a</year>
                <article-title>Identification of new and common mutations in the EPM2A gene in Lafora disease.</article-title>
                <source>Neurology</source>
                <volume>54</volume>
                <fpage>488</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">10668720</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.minassian.2000b.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ianzano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meloche</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                </person-group>
                <year>2000b</year>
                <article-title>Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy.</article-title>
                <source>Neurology</source>
                <volume>55</volume>
                <fpage>341</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10932264</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.minassian.1998.171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herbrick</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huizenga</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soder</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mungall</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunham</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>CY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jardim</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satishchandra</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snead</surname>
                    <given-names>OC</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Lopes-Cendes</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsui</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.</article-title>
                <source>Nat Genet</source>
                <volume>20</volume>
                <fpage>171</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9771710</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.mittal.2007.753">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mittal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubey</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment.</article-title>
                <source>Hum Mol Genet</source>
                <volume>16</volume>
                <fpage>753</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">17337485</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.nanba.1999.664">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nanba</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maegaki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Epileptic negative myoclonus induced by carbamazepine in a child with BECTS. Benign childhood epilepsy with centrotemporal spikes.</article-title>
                <source>Pediatr Neurol</source>
                <volume>21</volume>
                <fpage>664</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10513696</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.niittyl_.2006.11815">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Niittyl&#x000e4;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comparot-Moss</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lue</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messerli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trevisan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seymour</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gatehouse</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villadsen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeeman</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Similar protein phosphatases control starch metabolism in plants and glycogen metabolism in mammals.</article-title>
                <source>J Biol Chem</source>
                <volume>281</volume>
                <fpage>11815</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16513634</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.nitschke.2013.756">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nitschke</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmieder</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Awrey</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Israelian</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heydenreich</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleinpeter</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steup</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease.</article-title>
                <source>Cell Metab</source>
                <volume>17</volume>
                <fpage>756</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">23663739</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.pederson.2013.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pederson</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epp</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weaver</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pencea</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roach</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frankland</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Inhibiting glycogen synthesis prevents lafora disease in a mouse model.</article-title>
                <source>Ann Neurol</source>
                <volume>74</volume>
                <fpage>297</fpage>
                <lpage>300</lpage>
                <pub-id pub-id-type="pmid">23913475</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.pichiecchio.2008.342">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pichiecchio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veggiotti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardinali</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longaretti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poloni</surname>
                    <given-names>GU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uggetti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Lafora disease: spectroscopy study correlated with neuropsychological findings.</article-title>
                <source>Eur J Paediatr Neurol</source>
                <volume>12</volume>
                <fpage>342</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18063398</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.serratosa.1999.345">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallardo</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anta</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Bernabe</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindhout</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Augustijn</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tassinari</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malafosse</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topcu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grid</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dravet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkovic</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Cordoba</surname>
                    <given-names>SR</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).</article-title>
                <source>Hum Mol Genet</source>
                <volume>8</volume>
                <fpage>345</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">9931343</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.sharma.2013.9482">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mukherjee</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rao</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iyengar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shankar</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satishchandra</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jana</surname>
                    <given-names>NR</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.</article-title>
                <source>J Biol Chem</source>
                <volume>288</volume>
                <fpage>9482</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">23408434</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.sharma.2012.6830">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulherkar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mukherjee</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jana</surname>
                    <given-names>NR</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Malin regulates Wnt signaling pathway through degradation of dishevelled2.</article-title>
                <source>J Biol Chem</source>
                <volume>287</volume>
                <fpage>6830</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22223637</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.singh.2009.715">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes.</article-title>
                <source>Hum Mutat</source>
                <volume>30</volume>
                <fpage>715</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">19267391</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.singh.2012.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Phenotype variations in Lafora progressive myoclonus epilepsy: possible involvement of genetic modifiers?</article-title>
                <source>J Hum Genet.</source>
                <year>2012</year>
                <volume>57</volume>
                <fpage>283</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">22456482</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.singh.2006.e48">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sethi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francheschetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riggio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avanzini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado-Escueta</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>e48</fpage>
                <pub-id pub-id-type="pmid">16950819</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.singh.2012.1440">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhadauriya</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Lafora disease E3 ubiquitin ligase malin is recruited to the processing bodies and regulates the microRNA-mediated gene silencing process via the decapping enzyme Dcp1a.</article-title>
                <source>RNA Biol</source>
                <volume>9</volume>
                <fpage>1440</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23131811</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.singh.2005.347">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchiyama</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moriyama</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirose</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizoguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawaishi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamakawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.</article-title>
                <source>J Hum Genet</source>
                <volume>50</volume>
                <fpage>347</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">16021330</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.tagliabracci.2008.33816">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tagliabracci</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segvich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Depaoli-Roach</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roach</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.</article-title>
                <source>J Biol Chem</source>
                <volume>283</volume>
                <fpage>33816</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">18852261</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.traor_.2009.319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Traor&#x000e9;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landour&#x000e9;</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motley</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sangar&#x000e9;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meilleur</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulibaly</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traor&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niar&#x000e9;</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mochel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Pean</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vortmeyer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mani</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischbeck</surname>
                    <given-names>KH</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease.</article-title>
                <source>Neurogenetics.</source>
                <volume>10</volume>
                <fpage>319</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">19322595</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.turnbull.2011.e1002037">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DePaoli-Roach</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cortez</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pencea</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiberia</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piliguian</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roach</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <article-title>PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease.</article-title>
                <source>PLoS Genet.</source>
                <year>2011</year>
                <volume>7</volume>
                <fpage>e1002037</fpage>
                <pub-id pub-id-type="pmid">21552327</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.turnbull.2014.442">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epp</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldsmith</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pencea</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frankland</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <article-title>PTG protein depletion rescues malin-deficient Lafora disease in mouse.</article-title>
                <source>Ann Neurol.</source>
                <year>2014</year>
                <volume>75</volume>
                <fpage>442</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">24419970</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.turnbull.2012.2684">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lohi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiberia</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Omer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakrabarty</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyagi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pencea</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <article-title>Early-onset Lafora body disease.</article-title>
                <source>Brain.</source>
                <year>2012</year>
                <volume>135</volume>
                <fpage>2684</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">22961547</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.turnbull.2008.240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ren</surname>
                    <given-names>ZP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muralitharan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naranian</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Lafora progressive myoclonus epilepsy: disease course homogeneity in a genetic isolate.</article-title>
                <source>J Child Neurol</source>
                <volume>23</volume>
                <fpage>240</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">18263761</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.villanueva.2006.788">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alvarez-Linera</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>MRI volumetry and proton MR spectroscopy of the brain in Lafora disease.</article-title>
                <source>Epilepsia</source>
                <volume>47</volume>
                <fpage>788</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">16650146</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.wang.2002.2377">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuckey</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wishart</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.</article-title>
                <source>J Biol Chem</source>
                <volume>277</volume>
                <fpage>2377</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">11739371</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.worby.2006.30412">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Worby</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gentry</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.</article-title>
                <source>J Biol Chem</source>
                <volume>281</volume>
                <fpage>30412</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16901901</pub-id>
              </element-citation>
            </ref>
            <ref id="lafora.REF.worby.2008.4069">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Worby</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gentry</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG).</article-title>
                <source>J Biol Chem</source>
                <volume>283</volume>
                <fpage>4069</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">18070875</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="lafora.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="lafora.Suggested_Reading.reflist0">
            <ref id="lafora.REF.noebels">
              <mixed-citation publication-type="book">Noebels JL. The inherited epilepsies. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. New York, NY: McGraw-Hill. Chap 230.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="lafora.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="lafora.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://mni.mcgill.ca/">Montreal Neurological Institute and Hospital</ext-link>
          </p>
        </sec>
        <sec id="lafora.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>22 January 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>3 November 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 December 2007 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>2 January 2007 (ea) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
